Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Want a daily digest of the top Nashville news?
Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.
Want a daily digest of the top Columbus news?
Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.
Want a daily digest of the top Dallas news?
Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
The Pfizer logo. Photo: Spencer Platt/Getty Images
The Washington Post's story this week on how Pfizer opted out of pursuing a link between one of its blockbuster drugs and Alzheimer's prevention may have been overblown, Derek Lowe writes in Science Translational Medicine's blog.
The state of play: Undertaking an Alzheimer's trial is a huge endeavor, Lowe argues, and is both risky and expensive. "The clinical success rate for Alzheimer's trials is arguably zero per cent," he writes.
- Thus, the data from Pfizer's insurance claims aren't enough to launch an ambitious clinical trial.
- It's also illogical to think that a drug company would have sat on a potential Alzheimer's prevention — which would be worth a fortune.
- The link between anti-inflammatory drugs and Alzheimer's has been explored before, meaning that it's not like Pfizer kept completely ground-breaking information secret.
Go deeper: The outlook for Alzheimer's research keeps getting bleaker